<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05040217</url>
  </required_header>
  <id_info>
    <org_study_id>UCSD-BDNF1</org_study_id>
    <nct_id>NCT05040217</nct_id>
  </id_info>
  <brief_title>A Clinical Trial of AAV2-BDNF Gene Therapy in Early Alzheimer's Disease and Mild Cognitive Impairment</brief_title>
  <official_title>A Phase I Study to Assess the Safety, Tolerability and Preliminary Efficacy of AAV2-BDNF [Adeno-Associated Virus (AAV)-Based, Vector-Mediated Delivery of Human Brain Derived Neurotrophic Factor] in Subjects With Early Alzheimer's Disease and Mild Cognitive Impairment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mark Tuszynski</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Case Western Reserve University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ohio State University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Diego</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a first-in-human clinical trial to test whether a protein administered into the brain&#xD;
      continuously by gene therapy, Brain-Derived Neurotrophic Factor (BDNF), will slow or prevent&#xD;
      cell loss in the brains of people affected by Alzheimer's disease and Mild Cognitive&#xD;
      Impairment. The protein may also activate cells in the brain that have not yet deteriorated.&#xD;
      Gene therapy refers to the use of a harmless virus to have brain cells make the potentially&#xD;
      protective protein, BDNF.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open label Phase I clinical trial of AAV2-BDNF gene therapy for early Alzheimer's&#xD;
      Disease (AD) and Mild Cognitive Impairment (MCI) in 12 participants.&#xD;
&#xD;
      BDNF is a nervous system growth factor that regulates neuronal function in key memory&#xD;
      circuits of the brain (the entorhinal cortex and hippocampus). BDNF reduces cell loss,&#xD;
      stimulates cell function, and builds new connections (synapses) between brain cells in animal&#xD;
      models.&#xD;
&#xD;
      This clinical trial will use techniques of gene therapy because the candidate therapeutic&#xD;
      protein, BDNF, does not cross the blood brain barrier (BBB). Two previous clinical programs&#xD;
      of Nerve Growth Factor (NGF) gene therapy for AD and Neurturin gene therapy for Parkinson's&#xD;
      disease in over 120 patients provided evidence that degenerating neurons respond to growth&#xD;
      factors with classic &quot;trophic&quot; responses in the human brain.&#xD;
&#xD;
      Participants will undergo one gene transfer procedure. Thus, dosing is performed only once,&#xD;
      and repeat dosing or daily medications are not expected to be required.&#xD;
&#xD;
      12 participants will be enrolled in this Phase I trial, 6 with early AD and 6 with MCI.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2021</start_date>
  <completion_date type="Anticipated">March 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>This study aims to reduce neuronal loss and rebuild synapses in the brain of patients with Alzheimer's Disease (AD) and Mild Cognitive Impairment (MCI). A total of 12 subjects will be enrolled: subjects 1-6 will have a diagnosis of AD and subjects 7-12 will have a diagnosis of MCI. The gene therapy vector will consist of adeno-associated virus serotype 2 (AAV2) and will be stereotaxically administered into the brain under MRI guidance. Subjects will be followed over a pre-determined study time duration of 24 months, and indefinitely thereafter.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety as assessed by mumber of participants with treatment-related adverse events assessed on MRI scan</measure>
    <time_frame>24 months</time_frame>
    <description>Number of participants with treatment-related adverse events assessed on MRI scan</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Memory change tested on Ray Auditory Verbal Learning Task</measure>
    <time_frame>24 months</time_frame>
    <description>Memory tested on Ray Auditory Verbal Learning Task</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Memory change tested on Benson Complex Figure Draw and Memory</measure>
    <time_frame>24 months</time_frame>
    <description>Memory tested on Benson Complex Figure Draw and Memory</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy on PET scan reflected by change in fluorodeoxyglucose (FDG) PET scan</measure>
    <time_frame>24 months</time_frame>
    <description>FDG PET scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Biomarkers including CSF amyloid, tau and neurofilament</measure>
    <time_frame>24 months</time_frame>
    <description>CSF studies of amyloid, tau and neurofilament</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Memory change tested on mini-mental status examination (MMSE)</measure>
    <time_frame>24 months</time_frame>
    <description>MMSE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Memory tested on Alzheimer's Disease Assessment Scale, Cognitive component (ADAS-Cog)</measure>
    <time_frame>24 months</time_frame>
    <description>ADAS-Cog</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>Gene transfer of AAV2-BDNF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Up to 12 subjects will receive open-label AAV2-BDNF</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>AAV2-BDNF Gene Therapy</intervention_name>
    <description>AAV2-BDNF is a genetically engineered adeno-associated virus serotype 2 (AAV-2) that expresses the human BDNF cDNA.</description>
    <arm_group_label>Gene transfer of AAV2-BDNF</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AAV2-BDNF Gene Therapy</intervention_name>
    <description>Gene therapy is a biological therapy delivering the BDNF gene to the brain</description>
    <arm_group_label>Gene transfer of AAV2-BDNF</arm_group_label>
    <other_name>Growth Factor Gene Therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  diagnosis of probable Alzheimer's Disease (AD) within 3 years of memory loss&#xD;
&#xD;
          -  diagnosis of Mild Cognitive Impairment&#xD;
&#xD;
          -  age between 50-80 years&#xD;
&#xD;
          -  resident of San Diego or Orange Counties in California, or Ohio.&#xD;
&#xD;
          -  primary language English with no aphasia (no communication impairment)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        â€¢ seizure disorder&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Tuszynski, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Diego</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lori Graham</last_name>
    <phone>858-822-3372</phone>
    <email>ljgraham@ucsd.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Michelle Magana Mendoza</last_name>
    <phone>858-822-7438</phone>
    <email>mmaganamendoza@ucsd.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of California - San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92093-0626</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lori Graham, B.S.</last_name>
      <phone>858-822-3372</phone>
      <email>ljgraham@ucsd.edu</email>
    </contact>
    <contact_backup>
      <last_name>Mark Tuszynski, MD, PhD</last_name>
      <phone>858-534-8857</phone>
      <phone_ext>Tuszynski</phone_ext>
      <email>mtuszynski@ucsd.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Mark Tuszynski, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gabriel Leger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Case Western Reserve University</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Parianne Fatica, B.S.</last_name>
      <phone>216-464-6474</phone>
      <email>Parianne.Fatica@UHhospitals.org</email>
    </contact>
    <investigator>
      <last_name>Alan Lerner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Nagahara AH, Merrill DA, Coppola G, Tsukada S, Schroeder BE, Shaked GM, Wang L, Blesch A, Kim A, Conner JM, Rockenstein E, Chao MV, Koo EH, Geschwind D, Masliah E, Chiba AA, Tuszynski MH. Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease. Nat Med. 2009 Mar;15(3):331-7. doi: 10.1038/nm.1912. Epub 2009 Feb 8.</citation>
    <PMID>19198615</PMID>
  </results_reference>
  <results_reference>
    <citation>Nagahara AH, Tuszynski MH. Potential therapeutic uses of BDNF in neurological and psychiatric disorders. Nat Rev Drug Discov. 2011 Mar;10(3):209-19. doi: 10.1038/nrd3366. Review.</citation>
    <PMID>21358740</PMID>
  </results_reference>
  <results_reference>
    <citation>Nagahara AH, Mateling M, Kovacs I, Wang L, Eggert S, Rockenstein E, Koo EH, Masliah E, Tuszynski MH. Early BDNF treatment ameliorates cell loss in the entorhinal cortex of APP transgenic mice. J Neurosci. 2013 Sep 25;33(39):15596-602. doi: 10.1523/JNEUROSCI.5195-12.2013.</citation>
    <PMID>24068826</PMID>
  </results_reference>
  <results_reference>
    <citation>Tuszynski MH, Yang JH, Barba D, U HS, Bakay RA, Pay MM, Masliah E, Conner JM, Kobalka P, Roy S, Nagahara AH. Nerve Growth Factor Gene Therapy: Activation of Neuronal Responses in Alzheimer Disease. JAMA Neurol. 2015 Oct;72(10):1139-47. doi: 10.1001/jamaneurol.2015.1807.</citation>
    <PMID>26302439</PMID>
  </results_reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>June 21, 2021</study_first_submitted>
  <study_first_submitted_qc>September 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 10, 2021</study_first_posted>
  <last_update_submitted>September 1, 2021</last_update_submitted>
  <last_update_submitted_qc>September 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Diego</investigator_affiliation>
    <investigator_full_name>Mark Tuszynski</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Mild Cognitive Impairment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitogens</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

